Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783717 | 1.00 | GBA1 (0.41) | GBA1ALDH1A1CYP1A2MAN2B1GRM2 | |
| SCHEMBL10337392 | 0.89 | MAN2B1 (0.38) | GBA1ALDH1A1CYP1A2MAN2B1GRM2 | |
| SCHEMBL10337510 | 0.87 | PLA2G1B (0.35) | ALDH1A1CYP1A2MAN2B1GRM2CHRNB2 | |
| SCHEMBL3146990 | 0.84 | GBA1 (0.41) | GBA1MAN2B1TP53GAA | |
| SCHEMBL9323835 | 0.83 | ALDH1A1 (0.41) | ALDH1A1CYP1A2MAN2B1GRM2 | |
| SCHEMBL8517964 | 0.83 | CYP1A2 (0.39) | GBA1CYP1A2TP53 | |
| SCHEMBL11331181 | 0.81 | PIK3CD (0.40) | GBA1 | |
| SCHEMBL7611955 | 0.79 | PIK3CD (0.34) | GBA1TP53GAA | |
| SCHEMBL13261436 | 0.78 | GBA1 (0.41) | GBA1ALDH1A1CYP1A2MAN2B1PTGS1 | |
| SCHEMBL4416368 | 0.78 | GBA1 (0.41) | GBA1ALDH1A1CYP1A2MAN2B1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653117-B2 | Composition comprising at least one oxazoline to inhibit migration of langerhans cells, and uses thereof | LABORATOIRES EXPANSCIENCE (FR) | 2014-02-18 | — | — | US | disclosed |
| US-8304453-B2 | Composition comprising at least one alkanolamide to inhibit migration of langerhans cells and uses therof | LABORATOIRES EXPANSCIENCE (FR) | 2012-11-06 | — | — | US | disclosed |
| US-8236836-B2 | Antiinflammatory agents, soothing agents, enzyme inhibitors, chelate compounds or alkanolamides using oxazoline derivatives | LABORATOIRES EXPANSCIENCE (FR) | 2012-08-07 | — | — | US | disclosed |
| US-20090137453-A1 | COMPOSITION COMPRISING AT LEAST ONE OXAZOLINE TO INHIBIT MIGRATION OF LANGERHANS CELLS, AND USES THEREOF | MSIKA PHILIPPE | 2009-05-28 | — | — | US | disclosed |
| US-20060194881-A1 | Composition comprising at least one alkanolamide to inhibit megration of langerhans cells and uses therof | MSIKA PHILIPPE | 2006-08-31 | — | — | US | disclosed |
| US-20050075380-A1 | Composition comprising at least one oxazolin for inhibiting langerhans cell migratio, and uses thereof | LABORATOIRES EXPANSCIENCE (FR) | 2005-04-07 | — | — | US | disclosed |
| US-20050075397-A1 | Composition comprising at least one alkanolamide for inhibiting langerhans cells migration, and uses thereof | LABORATOIRES EXPANSCIENCE (FR) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075397-A1 | Composition comprising at least one alkanolamide for inhibiting langerhans cells migration, and uses thereof | ARG1, CPA3, MIF | GBA1 836/4885ALDH1A1 1325/4885CYP1A2 3181/4885 |
| US-20090137453-A1 | COMPOSITION COMPRISING AT LEAST ONE OXAZOLINE TO INHIBIT MIGRATION OF LANGERHANS CELLS, AND USES THEREOF | ARG1, MIF, ZAP70 | GBA1 1453/4885ALDH1A1 1440/4885CYP1A2 2904/4885 |
| US-20050075380-A1 | Composition comprising at least one oxazolin for inhibiting langerhans cell migratio, and uses thereof | MIF, CUTA, ARG1 | GBA1 777/4885ALDH1A1 1919/4885CYP1A2 4017/4885 |
| US-20060194881-A1 | Composition comprising at least one alkanolamide to inhibit megration of langerhans cells and uses therof | TPSG1, CPA3, CTSF | GBA1 664/4885ALDH1A1 2203/4885CYP1A2 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.